# Laura Lowe Furge

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8901225/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 29 papers | 289 citations | 1306789 7 h-index | 887659 17 g-index |
| 32 all docs | 32 docs citations | 32 times ranked | 438 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction. Biochemistry and Molecular Biology Education, 2006, 34, 66-74. | 0.5 | 136 |
| 2 | Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica, 2014, 44, 309-319. | 0.5 | 39 |
| 3 | Vertical and horizontal integration of bioinformatics education. Biochemistry and Molecular Biology Education, 2009, 37, 26-36. | 0.5 | 27 |
| 4 | Molecular Dynamics of CYP2D6 Polymorphisms in the Absence and Presence of a Mechanism-Based Inactivator Reveals Changes in Local Flexibility and Dominant Substrate Access Channels. PLoS ONE, 2014, 9, e108607. | 1.1 | 24 |
| 5 | Molecular Analysis and Modeling of Inactivation of Human CYP2D6 by Four Mechanism Based Inactivators. Drug Metabolism Letters, 2012, 6, 7-14. | 0.5 | 16 |
| 6 | HPLC determination of caffeine and paraxanthine in urine: An assay for cytochrome P450 1A2 activity. Biochemistry and Molecular Biology Education, 2007, 35, 138-144. | 0.5 | 9 |
| 7 | Substituted Imidazole of 5-Fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates Cytochrome P450 2D6 by Protein Adduction. Drug Metabolism and Disposition, 2011, 39, 974-983. | 1.7 | 9 |
| 8 | Innovation in the Biochemistry/Molecular biology laboratory. Biochemistry and Molecular Biology Education, 2015, 43, 66-67. | 0.5 | 4 |
| 9 | CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712. Drug Metabolism and Disposition, 2018, 46, 1106-1117. | 1.7 | 4 |
| 10 | Rolapitant Is a Reversible Inhibitor of CYP2D6. Drug Metabolism and Disposition, 2019, 47, 567-573. | 1.7 | 4 |
| 11 | Oltipraz inhibits inducible nitric oxide synthase in vitro and inhibits nitric oxide production in activated microglial cells. Archives of Biochemistry and Biophysics, 2004, 424, 163-170. | 1.4 | 3 |
| 12 | Mechanism-Based Inactivation of Human Cytochrome P450 3A4 by Two Piperazine-Containing Compounds. Drug Metabolism and Disposition, 2014, 42, 2087-2096. | 1.7 | 3 |
| 13 | Commentary: Innovation in the biochemistry/molecular biology laboratory. Biochemistry and Molecular Biology Education, 2012, 40, 23-23. | 0.5 | 2 |
| 14 | Commentary: Innovation in the biochemistry/molecular biology laboratory. Biochemistry and Molecular Biology Education, 2013, 41, 11-11. | 0.5 | 2 |
| 15 | Commentary: Innovation in the biochemistry/molecular biology laboratory. Biochemistry and Molecular Biology Education, 2014, 42, 39-40. | 0.5 | 2 |
| 16 | Tryptophan-75 Is a Low-Energy Channel-Gating Residue that Facilitates Substrate Egress/Access in Cytochrome P450 2D6. Drug Metabolism and Disposition, 2021, 49, 179-187. | 1.7 | 2 |
| 17 | Experimental approaches to microarray analysis of tumor samples. Biochemistry and Molecular Biology Education, 2008, 36, 149-152. | 0.5 | 1 |
| 18 | Institutional review boards and educational research. Biochemistry and Molecular Biology Education, 2011, 39, 85-86. | 0.5 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Commentary: Innovation in the Biochemistry/Molecular Biology laboratory. Biochemistry and Molecular Biology Education, 2016, 44, 117-117. | 0.5 | 1 |
| 20 | Social ecology of the classroom: Issues of inclusivity. Biochemistry and Molecular Biology Education, 2015, 43, 1-2. | 0.5 | 0 |
| 21 | Toxicology and Carcinogenesis: A Course for Undergraduate Nonâ€Science Majors. FASEB Journal, 2006, 20, . | 0.2 | 0 |
| 22 | Performance tasks as activeâ€learning tools for nonâ€science majors. FASEB Journal, 2009, 23, 464.2. | 0.2 | 0 |
| 23 | Mechanismâ€Based Inhibition of Human Cytochrome P450 2D6 by Schering 66712. FASEB Journal, 2010, 24, 512.3. | 0.2 | 0 |
| 24 | CYP2D6 is the Major Metabolizing Enzyme of Metoclopramide. FASEB Journal, 2013, 27, 1007.2. | 0.2 | 0 |
| 25 | Metoclopramide is a Substrate but Not an Inactivator of CYP2D6. FASEB Journal, 2013, 27, 1007.1. | 0.2 | 0 |
| 26 | Interaction of Mechanismâ€Based Inactivators with Modified CYP2D6. FASEB Journal, 2013, 27, 1007.3. | 0.2 | 0 |
| 27 | Covalent Modification of CYP2D6 Following Inactivation by SCH66712. FASEB Journal, 2013, 27, 1007.4. | 0.2 | 0 |
| 28 | Interactions of Human CYP2D6 Polymorphisms with the Mechanismâ€Based Inactivator SCH 66712. FASEB Journal, 2015, 29, 716.12. | 0.2 | 0 |
| 29 | SCH 66712 and EMTPP are the First Potent Mechanismâ€Based Inactivators of Both Human CYP2D6 and CYP3A4. FASEB Journal, 2015, 29, 716.11. | 0.2 | 0 |